CanSino Biologics Inc. (688185.SH)DTaP-Hib-MCV4 combination vaccine initiated Phase I clinical trial and completed the first subject enrollment.

16:36 19/12/2025

CanSino (688185.SH) announced that the company's adhesion-free cell-free centibro B type influenza streptococcus (binding)-ACYW135 group meningococcal (binding) combination vaccine (referred to as "DTcP-Hib-MCV4 combination vaccine") has officially started phase I clinical trials recently, and the first subject has been enrolled.

CanSino Biologics Inc. (688185.SH) announced that the company's adsorbed-cell-free combined vaccine against hepatitis B, group C meningococcal conjugate vaccine, and group ACYW135 meningococcal conjugate vaccine (referred to as "DTcP-Hib-MCV4 combined vaccine") has officially started Phase I clinical trials recently, with the first subject successfully enrolled. The Phase I clinical trial is a randomized, partially blinded, dose-exploration, positive/placebo-controlled clinical trial to evaluate the safety and immunogenicity of the DTcP-Hib-MCV4 combined vaccine in the age group of 2 months to 6 years.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"